

FINAL PROGRAM

# 5<sup>th</sup> International Meeting on Aortic Diseases

New insights into an old problem

CHU Liège, APF



September 15-17

# 2016

Crowne Plaza Hotel  
Liège, Belgium

[www.chuliege-ima.be](http://www.chuliege-ima.be)



CHU  
de Liège



18 CREDITS



8 EBCP  
RECERTIFICATION  
POINTS

## 5<sup>th</sup> International Meeting on Aortic Diseases

New insights into an old problem

September 15-17 2016 • Liège • Belgium

I am really honored to welcome you to the **fifth edition** of the **International Meeting on Aortic Diseases** that is organized from **September 15 to 17, 2016** at the Crowne Plaza in Liège, Belgium.

This new edition is taking place in the historic center of Liège, during a famous Wallonian (local) festivity. The Crowne Plaza is at walking distance, but also from many hotels, and all facilities.

IMAD 2016 is focusing on new insights on basic research, as well as on the treatment of aortic valves, aneurysms, dissections (types A and B) and infection.

You are a vascular or a cardiac surgeon, you are a radiologist, a cardiologist, a geneticist, a biologist, an epidemiologist and/or any scientist, you are welcome in Liège. Please take the opportunity to share the experiences of the most renowned experts on aortic diseases, as well as to receive answers from them to any question you would have.

We are pleased to welcoming you in Liège to sharing with you another exciting conference on aortic diseases!

**Natzi Sakalihasan**

### Under the patronage of:



- University of Liège
- Cardiovascular Surgery Department of CHU of Liège
- Province of Liège
- APF (Aneurysmal Pathology Foundation)
- Faculty of Medicine, ULg

### Course Director:

**Natzi SAKALIHASAN**  
Liège, Belgium

### Co-Director:

**Jean-Olivier DEFRAIGNE**  
Liège, Belgium

### Scientific Committee:

**Matt BOWN**  
Cardiff, United Kingdom

**Audrey COURTOIS**  
Liège, Belgium

**Alessandro DELLA CORTE**  
Napoli, Italy

**John ELEFTERIADES**  
New Haven, USA

**Rebecka HULTGREN**  
Stockholm, Sweden

**Gregory JONES**  
Dunedin, New Zealand

**Nicos LABROPOULOS**  
Stony Brook, USA

**Frank LEDERLE**  
Minneapolis, USA

**Victor LEGRAND**  
Liège, Belgium

**Christoph NIENABER**  
London, United Kingdom

**Florence PINET**  
Lille, France

**Marc RADERMECKER**  
Liège, Belgium

**Juliette ALBUISSON**,  
Paris, France

**Eric ALLAIRE**,  
Créteil, France

**Valery ARAKELIAN**,  
Moscow, Russia

**George ASIMAKOPOULOS**,  
Bristol, United Kingdom

**Parla ASTARCI**,  
Bruxelles, Belgium

**Domenico BACCELLIERI**,  
Milan, Italy

**Jean-Pierre BECQUEMIN**,  
Champigny, France

**Yadav BHATTA**,  
Kathmandu, Nepal

**Colin BICKNELL**,  
London, United Kingdom

**Malenka BISSELL**,  
Oxford, United Kingdom

**Simon BODY**,  
Boston, USA

**Jan BRUNKWALL**,  
Köln, Germany

**Rachel CLOUGH**,  
London, United Kingdom

**Ronald DALMAN**,  
Stanford, USA

**Lazar B. DAVIDOVIC**,  
Surcin, Serbia

**Julie DE BACKER**,  
Gent, Belgium

**Frédéric COLLART**,  
Marseille, France

**Jean-Paul DE VRIES**,  
Nieuwegein, The Netherlands

**Barry DOYLE**,  
Perth Australia

**Helena DULGHERU**,  
Liège, Belgium

**Rodolphe DURIEUX**,  
Liège, Belgium

**Hans-Henning ECKSTEIN**,  
Munich, Germany

**Sean ENGLISH**,  
St Louis, USA

**Per ERIKSSON**,  
Stockholm, Sweden

**Daniel FINK**,  
Jerusalem, Israel

**Peter FRAMBACH**,  
Luxembourg

**Jullien GAER**,  
Harefield, United Kingdom

**Christian GASSER**,  
Stockholm, Sweden

**Athanasios GIANNOUKAS**,  
Larissa, Greece

**Evaldas GIRDAUSKAS**,  
Bad Berka, Germany

**Jonathan GOLLEDGE**,  
Townsville, Australia

**David GUZZARDI**,  
Calgary, Canada

**Grégory HANS**,  
Liège, Belgium

**Dominic HOWARD**,  
Oxford, United Kingdom

**Arne S IJPM**,  
Rotterdam, the Netherlands

**Heinz JAKOB**,  
Essen, Germany

**Fabien KOSKAS**,  
Paris, France

**Dung LE HUU**,  
Ho Chi Minh, Vietnam

**Jan LINDEMAN**,  
Leiden, The Netherlands

**Jes LINDHOLT**,  
Viborg, Denmark

**Bart LOEYS**,  
Antwerp, Belgium

**Lars MAEGDEFESSEL**,  
Stockholm, Sweden

**Danielle MAJOOR**,  
Rotterdam, The Netherlands

**Miltiadis MATSAGKAS**,  
Larissa, Greece

**Bart MEURIS**,  
Leuven, Belgium

**Jean-Baptiste MICHEL**,  
Paris, France

**Rita MILEWSKI**,  
Philadelphia, USA

**Thomas MODINE**,  
Lille, France

**Firas MUSSA**,  
New York, USA

**Paul NORMAN**,  
Fremantle, Australia

**Betty NUSGENS**,  
Liege, Belgium

**Domenico PALOMBO**,  
Genova, Italy

**Luc PIERARD**,  
Liège, Belgium

**Janet POWELL**,  
London, United Kingdom

**Cesare QUARTO**,  
London, United Kingdom

**Morgan SALMON**,  
Charlottesville, USA

**Thanos SARATZIS**,  
Leicester, United Kingdom

**Toru SUZUKI**,  
Leicester, United Kingdom

**Apostolos TASSIOPOULOS**,  
Stony brook, USA

**Vincent TCHANA SATO**,  
Liège, Belgium

**Gilbert R. UPCHURCH**,  
Charlottesville, USA

**Rao Srinivasa VALLABHANENI**,  
Liverpool, United Kingdom

**Isabelle VAN HERZEELE**,  
Gent, Belgium

**Eric VERHOEVEN**,  
Nürnberg, Germany

**Emiliano VOTTA**,  
Milan, Italy

**Pascal VRANCKX**,  
Hasselt, Belgium

**Anders WANHAINEN**,  
Uppsala, Sweden

**James YEH**,  
London, United Kingdom


**Koichi YOSHIMURA**,  
Yamaguchi, Japan



Thursday September 15		Friday September 16	
08.30	<b>Genetics of aortic diseases</b>	08.30	<b>Aortic dissection</b>
10.00	<b>Coffee break</b>	10.00	<b>Coffee break</b>
10.30	<b>Epidemiology and treatment of AAA</b>	10.30	<b>Challenging cases of aortic dissection</b>
12.30	<b>Lunch break</b>	12.30	<b>Lunch break</b>
13.30	<b>New advances in physiopathology of aortic diseases</b>	13.30	<b>TEVAR for TAA</b>
15.00	<b>Generalities on medical treatment of AAA</b>	15.00	<b>Potpourri related with aortic diseases</b>
16.45	<b>Coffee break</b>	16.40	<b>Coffee break</b>
17.15	<b>Causes and management of ruptured AAA</b>	17.10	<b>Generalities on EVAR</b>
19.05	<b>End of the sessions</b>	19.15	<b>End of the sessions</b>

Saturday September 17	
08.30	<b>Risk stratification in BAV aortopathy: new concepts</b>
09.45	<b>Coffee break</b>
10.15	<b>Ascending aorta</b>
11.30	<b>Industry sponsored symposium</b>
12.30	<b>Lunch break</b>
13.30	<b>Aortic arch</b>
15.00	<b>Aortic valves</b>
17.00	<b>Awards ceremony</b>
17.30	<b>Adjournment</b>

20.00 **IMAD Official dinner - Thursday**  
**Palais Provincial**  
 All delegates are welcome to register with one guest. Seated dinner.  
 Participation fee: 55 € per person.





08.00 **Welcome address, Natzi Sakalihasan**  
**Distinguished lecture, Frank Lederle**

## I **Genetics of aortic diseases** **Greg Jones, Matthew Bown**

- 08.30 Extra-aortic cardiovascular features in Marfan syndrome - Relevance and management, **Julie De Backer**
- 08.38 Whole blood DNA methylation analysis in AAA; an epigenome-wide association study, **Greg Jones**
- 08.46 Combining Mendelian genetics and genetic epidemiology for AAA, **Juliette Albuissou**
- 08.54 New insights on genetic aspect of aortic disease, **John Elefteriades**
- 09.02 Does sex matter in aortic aneurysm and dissection? **Bart Loeys**
- 09.10 Genetic risk profile: insights from family based AAA NGS analysis, **Danielle Majoor, Arne S. Ijpm**
- 09.26 Discussion

### **Short communications from selected papers**

- 09.35 • High heritability of abdominal aortic aneurysms – a population-based twin-study, **Trine Maria Mejnert Joergensen**
- 09.40 • Global and gene specific DNA methylation is associated with Abdominal Aortic Aneurysms, **Bradley Toghil**
- 09.45 • End-stage human aneurysm disease in different arterial positions is similar – aneurysm induction in mouse models however not, **Albert Busch**
- 09.50 • Phenotypic switching of SMCs is a potential therapeutic target in popliteal aneurysms, **Albert Busch**
- 09.55 • Resveratrol inhibits aortic root dilatation in the Fbn1C1039G/+ Marfan mouse model, **Vivian de Waard**

10.00 **Coffee break**

## I **Epidemiology and treatment of AAA** **Frank Lederle, Anders Wanhainen**

- 10.30 Findings from the Swedish AAA screening program, **Anders Wanhainen**
- 10.40 Is risk-factor targeted AAA screening the future? Data from the Oxford Vascular Study, **Dominic Howard**
- 10.50 Morphology of ruptured vs unruptured AAA, **Janet T. Powell**
- 11.00 AAA rupture in Stockholm, **Rebecka Hultgren**
- 11.10 Australian trials to identify treatments to slow AAA growth, **Jonathan Golledge**
- 11.20 AAA measurement and enlargement, **Frank Lederle**
- 11.30 CT-overestimation of AAA size severely impacts the cost-effectiveness of AAA repair, **Jan Lindeman**
- 11.40 Discussion

### **Short communications from selected papers**

- 12.10 • Immunopathology in patients with AAA, **Miroslav Prucha**
- 12.15 • How does it feel to have an abdominal aortic aneurysm – a patient-centered view, **Stephanie Tomee**
- 12.20 • Meta-analysis of the current prevalence of screen-detected abdominal aortic aneurysm in women, **Pinar Ulug**
- 12.25 • Diameter growth rate and future indication for surgery can be predicted with finite element analysis and semi-automatic diameter measurements in small abdominal aortic aneurysms, **Moritz Lindquist Liljeqvist**

12.30 **Lunch break**

## I **New advances in physiopathology of aortic diseases** **Audrey Courtois, Florence Pinet**

- 13.30 Inward neo-angiogenesis in aortic diseases, **Jean-Baptiste Michel**
- 13.38 NETosis is associated with abdominal aortic aneurysm rupture, **Sean English**
- 13.46 The translational story of the relationship between reversible pulmonary obstructive disease and AAA, **Jes Lindholt**
- 13.54 Non-coding RNA and aneurysm, clinical implications: from experimental animal models to therapeutics approaches, **Lars Maegdefessel**
- 14.02 Cell-specific expression of non coding RNA in human AAA: new approach to find biomarkers, **Florence Pinet**
- 14.10 Circulating miRNA associated with unstable abdominal aortic aneurysm PET positive, **Audrey Courtois**
- 14.18 Circulating vascular basement fragments are associated with the diameter of abdominal aorta, **Anders Wanhainen**
- 14.26 Discussion

### **Short communications from selected papers**

- 14.50 • Transdifferentiation of human dermal fibroblasts to smooth muscle like cells: a novel method to study the effect of MYH11 and ACTA2 variants in the aortic aneurysm wall, **Natalija Bogunovic**
- 14.55 • Live human arterial tissue slices for bench top research on pathophysiology of aortic aneurysms; up to 90 days *ex vivo* preservation, **Jorn Meekel**



## I Generalities on medical treatment of AAA

Gilbert R. Upchurch, Paul Norman

- 15.10 Where and why does thrombus develop in aortic disease, [Barry Doyle](#)
- 15.18 Focal adhesion Kinase is a novel target for pharmacotherapy of abdominal aortic aneurysm, [Koichi Yochimura](#)
- 15.26 Inhibition of aneurysmal progression by local PGG infusion in experimental porcine AAA, [Jes Lindholt](#)
- 15.34 TElmisartan in the management of abDominal aortic aneurYsm (TEDY): the study protocol for a randomized controlled trial, [Jonathan Golledge](#)
- 15.42 What is the role of the KLF4 during the development of abdominal aortic aneurysm, [Morgan Salmon](#)
- 15.50 The effect of metformin on AAA, [Ronald Dalman](#)
- 15.58 What do we know about AAA and diabetes and does it matter? [Paul Norman](#)
- 16.06 **Keynote lecture.** Medical treatment of the AAA in human. Fiction or reality? [Gilbert R. Upchurch](#)

16.14 Discussion

## Short communications from selected papers

- 16.30 • Inhibition of pathological vascular smooth muscle cell remodelling as a treatment strategy for abdominal aortic aneurysm, [Marc Bailey](#)
- 16.35 • Canonical TGFβ-signaling is triggered by inflammation in human non-syndromic aneurysm disease, but is not reflected by inducible AAA mouse models, [Albert Busch](#)
- 16.40 • Phenotyping of transgenic pigs to determine the suitability of xenografts in the treatment of aortic diseases, [Ewa Strauss](#)

16.45 **Coffee break**

## I Causes and management of ruptured AAA

Rebecka Hultgren, Ronald Dalman

- 17.15 The biology of AAA progression and rupture: beyond MMPs and inflammation, [Jan Lindeman](#)
- 17.23 Imaging alternatives in order to prevent rupture (volume vs diameter), [Christian Gasser](#)
- 17.31 Is the risk different for female or male FDRs to AAA patients? [Rebecka Hultgren](#)
- 17.39 Emergency EVAR – the new standard for almost every patient with a ruptured AAA (technique and own clinical data over 10 years, literature review), [Hans-Henning Eckstein](#)
- 17.47 Open repair of RAAA is always possible - is it always better? [Lazar Davidovic](#)
- 17.55 Prolonged or renewed ICU stay after AAA-repair - a “crash investigation”, [Anders Wanhainen](#)
- 18.03 TAVI, MAVI, TEVAR, EVAR - The end of standard cardiovascular surgery? Perspectives of a cardiac surgeon, [Daniel Fink](#)

18.11 Staged hybrid repair of extensive TAAA, [Gilbert R. Upchurch](#)

18.19 **Keynote lecture.** Lessons learned from IMPROVE trial, [Janet T. Powell](#)

18.27 Questions to experts & panel discussion

## Short communications from selected papers

- 18.40 • Management of visceral artery aneurysms: a 20-year single centre experience, [Gianfranco Filippone](#)
- 18.45 • Aortic size index could improve surveillance of women and men with AAA, [Rebecka Hultgren](#)
- 18.50 • How common is the classic triad of symptoms in patients with ruptured AAA? [Rebecka Hultgren](#)
- 18.55 • Survival disparity following AAA repair highlights inequality in socioeconomic status, [Manar Khashram](#)
- 19.00 • Patient reported quality and functional life after AAA repair, [Manar Khashram](#)

19.05 **End of the sessions**

20.00 **Official dinner (upon registration)**





## I Aortic dissection

**Natzi Sakalihasan, Christoph Nienaber**

- 08.30 Diagnostic algorithm for acute aortic dissection – imaging and biomarkers, **Toru Suzuki**
- 08.40 Therapeutic pathways in acute aortic dissection, **Cesare Quarto**
- 08.50 Individualized risk assessment in type B aortic dissection, **Rachel Clough**
- 09.00 Can we predict aortic size PRIOR to dissection? Yes! **John Elefteriades**
- 09.10 Computational modelling of type B aortic dissection: does it help manage patients? **Barry Doyle**
- 09.20 Initial experience in dissection of aorta in Nepal, **Yadav Bhatta**
- 09.30 **Keynote lecture. Christoph Nienaber**
- 09.40 Discussion

## 10.00 Coffee break

## I Challenging cases of aortic dissection

**Firas Mussa, Jean-Olivier Defraigne**

- 10.30 Aortic dissection – the great masquerader, **James Yeh**
- 10.40 Proximal aortic dissection – the role of the frozen elephant, **Heinz Jakob**
- 10.50 Proximal aortic dissection – the emerge of TEVAR, **George Asimakopoulos**
- 11.00 Staged repair of complex aortic dissection – safer or superfluous? **Jullien Gaer**
- 11.10 Retrograde aortic dissection after TEVAR: incidence, risk factors, precautions and treatment, **Firas Mussa**
- 11.20 Positive family history of aortic dissection dramatically increases dissection risk in family members, **John Elefteriades**
- 11.30 Clinical outcomes of TBADs in patients with connective tissue diseases (Marfan, Loeys-Dietz, etc.) are worse than in those without, **Firas Mussa**
- 11.40 Case presentation and discussion: severe lower extremity malperfusion in a patient with acute type A dissection, what is the priority? **Vincent Tchana-Sato**
- 11.50 Type B aortic dissection in the patient with MYLK variants. What is the best solution: TEVAR or open repair? **Vincent Tchana-Sato**
- 12.00 Questions to experts and panel discussion

## 12.30 Lunch break

## I TEVAR for TAA

**Eric Verhoeven, Hans-Henning Eckstein**

- 13.30 Open surgical conversion after TEVAR: incidence and treatment options, **Domenico Baccellieri**
- 13.39 Spinal cord ischemia in TAAA branched grafting, **Eric Verhoeven**
- 13.48 CSF drainage in TEVAR: anesthetic considerations, **Gregory Hans**
- 13.57 Neuromonitoring using motor and somatosensory evoked potentials in aortic surgery, **John Elefteriades**
- 14.06 Is there an increased risk to more complex fenestrated EVAR? **Eric Verhoeven**
- 14.15 Fenestrated and branched grafts: lessons after four years of the Windows trial, **Jean-Pierre Becquemin**
- 14.24 Consensus exercise on management of thoracic and thoracoabdominal aortic aneurysms in the United Kingdom, **Srinivasa R. Vallabhaneni**
- 14.33 Type B dissection: update on indications and results using a pragmatic policy, **Fabien Koskas**
- 14.42 Ask to experts and panel discussion

## I Potpourri related with aortic diseases

**Colin D. Bicknell, Apostolos Tassiopoulos**

- 15.00 Radiation protection for patient and staff during routine EVAR and TEVAR procedures, **Miltiadis Matsagkas**
- 15.08 Management aortic coarctation in 2016: surgery vs endovascular treatment, **Colin D. Bicknell**
- 15.16 Management of graft infection after EVAR-TEVAR. Can PET-CT predict the outcome of prosthetic graft infections? **Natzi Sakalihasan**
- 15.32 Extra anatomic bypass for congenital and acquired disorders of the thoracic aorta: indications, technique, results, **Valery Arakelyan**
- 15.47 **Keynote lecture. Medical errors during endovascular treatment for aortic diseases. How can we avoid them? Colin D. Bicknell**
- 15.57 Discussion
- Short communications from selected papers**
- 16.20 • Incidence, treatment and long-term clinical outcome in patients with aortic graft infections, **Jennifer Pettersson**
- 16.25 • Sex differences in outcomes after AAA repair in the United Kingdom, **Matthew Bown**
- 16.30 • Explantation of a fenestrated abdominal endograft with autologous venous reconstruction for infection, **Catherine Terry**

## 16.40 Coffee break

## I Generalities on EVAR

**Nicos Labropoulos, Isabelle Van Herzele**

Friday September 16

- 17.10 Impact of geometry and respiratory-induced deformation during snorkel/chimney and fenestrated endografts for complex abdominal aortic aneurysms, **Ronald Dalman**
- 17.20 Flow characteristics of Type II endoleaks. Does it matter? **Nicos Labropoulos**
- 17.30 Invisible endoleak after stent graft: a ghost or a myth? **Eric Allaire**
- 17.40 Apposition of the endograft post-EVAR. Improved technique to calculate and its importance to predict failure, **Jean-Paul de Vries**
- 17.50 Patients' compliance with post-EVAR follow-up and its impact on the outcome, **Athanasios Giannoukas**
- 18.00 Early and long-term outcomes after open or endovascular repair for abdominal aortic aneurysms in high-risk patients, **Domenico Palombo**
- 18.10 Renal function is the main predictor of acute kidney injury after endovascular abdominal aortic aneurysm repair, **Thanos Saratzis**
- 18.20 Is there a role for use of endoanchors in EVAR or TEVAR procedures? **Apostolos Tassiopoulos**
- 18.30 Profile of secondary interventions after EVAR in current practice: how are they triggered and what are the implications for surveillance? **Srinivasa R. Vallabhaneni**
- 18.50 Case presentation, **Isabelle Van Herzeele**
- 19.00 Questions to experts and panel discussion
- 19.15 **End of the sessions**

## Notes





## I Risk stratification in BAV aortopathy: new concepts Alessandro Della Corte, Simon Body

- 08.30 Genotype-based risk stratification of BAV disease: dream or reality? *Simon Body*
- 08.40 Implementing phenotype-based risk stratification of BAV aortopathy in surgical practice, *Evaldas Girdauskas*
- 08.50 Structural finite element modelling of the bicuspid root to understand disease progression, *Emiliano Votta*
- 09.00 Functional imaging of the BAV aorta to predict aortopathy progression, *Malenka Bissell*
- 09.10 Identifying circulating biomarkers of BAV aortopathy risk, *Alessandro Della Corte*
- 09.20 How to integrate imaging and biochemistry into risk stratification of bicuspid aortopathy, *David Guzzardi*
- 09.30 Questions to experts and discussion

### Short communications from selected papers

- 09.35 • Aortopathy in patients with a bicuspid aortic valve: a process beyond normal cardiovascular ageing, *Nimrat Grewal*
- 09.40 • The role of hemodynamics and shear stress on the ascending aortic wall in patients with a bicuspid aortic valve, *Nimrat Grewal*

### 09.45 Coffee break

## I Ascending aorta John Elefteriades, Jean-Olivier Defraigne

- 10.15 The pathology of thoracic aortic aneurysm, *Per Eriksson*
- 10.25 Twenty-five year outcome of composite graft aortic root replacement: near "curative" impact on aortic root disease, *John Elefteriades*
- 10.35 Is there really research-based evidence for a guideline dimension for ascending aortic aneurysm repair? *Simon Body*
- 10.45 How to classify the dilatations of the ascending aorta? *Alessandro Della Corte*
- 10.55 Modeling of predissection aortic size in acute type A dissection: more than 90% fail to meet the guidelines for elective ascending replacement, *Rita K Milewski*
- 11.05 Management of aorto-ventricular tunnels: a rare cause (disregarded) of the heart failure in occidental countries. Single center experiences in HCMC, Vietnam, *Dung Le Huu, Natzi Sakalihasan*
- 11.15 Questions to experts and discussion

### 11.30 Industry sponsored symposium (See page 17)

### 12.30 Lunch break

## I Aortic arch Firas Mussa, Jan Brunkwall

- 13.30 Supraaortic debranching and TEVAR for arch aneurysms – is it a valid alternative for open surgery? (Single center series on > 50 pts), *Hans-Henning Eckstein*
- 13.40 Branched endograft vs. chimney techniques for treating complex arch lesions. Which is best, when and why, *Firas Mussa*
- 13.50 Update on total arch endovascular repair, *Rachel Clough*
- 14.00 Various cardiac access routes to treat ascending aortic and arch lesions: advantages and limitations, *Firas Mussa*
- 14.10 Does the bovine arch have any influence on the outcome of arch stentgrafting in dissections? *Jan Brunkwall*
- 14.20 Distal aortic reintervention after surgery for acute DeBakey type I or II aortic dissection: open vs. endovascular repair, *Rita K. Milewski*
- 14.30 **Keynote lecture.** Hybrid stent-grafts: factotum of open surgery of the aortic arch? *Fabien Koskas*
- 14.40 Discussion
- 14.50 **Short communications from selected papers**
  - Deep hypothermia with retrograde cerebral perfusion – as method of brain protections in ascending aorta and arch aneurysms surgery, *Vitalii Kravchenko*
  - Aneurysm at the site of repair of coarctation of aorta: frequency, methods of treatment, results, *Vitalii Kravchenko*

## I Aortic valves Marc Radermecker, Victor Legrand

- 15.00 TAVI indications, *Luc Piérard*
- 15.10 New imaging modalities for assessment of TAVI procedure and results, *Helena Dulgheru*
- 15.20 Critical analysis of recent registries and randomized trials, *Victor Legrand*
- 15.30 Choice of the best transcatheter site for implantation, *Marc Radermecker*
- 15.40 Off label indications: where are we? *Thomas Modine*
- 15.50 Antithrombotic treatment: DAPT or OAC? *Pascal Vranckx*
- 16.00 Rapid deployment aortic bioprosthesis in patients with small aortic annulus, *Frédéric Collart*
- 16.10 Valve fair: review of actual and future devices, *Peter Frambach*
- 16.20 New insight of percutaneous native aortic valve resection prior to TAVI, *Parla Astarci*
- 16.30 Sutureless aortic valve replacement: worldwide experience, *Bart Meuris*
- 16.40 Case presentation and discussion: valve thrombosis after transcatheter aortic valve implantation, *Rodolphe Durieux*
- 16.50 Discussion
- 17.00 **Closing remarks & Awards ceremony**
- 17.30 **Adjournment**



## ePosters presented during the morning and lunch breaks (Saturday at 9.45 and 12.30)

Jury: Firas Mussa, Hans-Henning Eckstein, Betty Nusgens

- Adventitial adipogenic degeneration: an unidentified contributor to aortic wall weakening in the abdominal aortic aneurysm  
S.A. Doderer, V.B.C. Kokje, J.F. Hamming, J.H. van Bockel, J.H.N. Lindeman
- PET-TC utility to assess the abdominal aortic aneurysm growth and its relationship with changes in energetic metabolism  
Angel Galindo, Guillermo Moñux, Javier Modrego, Roberto Delgado, Manuela Maria Hernandez, Antonio Jose Lopez-Farre, Francisco Javier Serrano
- Evidence of intimal tear in aortic intramural hematoma  
Gianfranco Filippone, Rosalba Franchino, Alessandro Ricasoli, Vincenzo Argano
- The application of metabolic profiling to aneurysm research  
Michele Greco, Mahim Qureshi, Vorkas Panagiotis, Elaine Holmes, Alun H Davies
- Preoperative fibrinogen levels and early outcome following endovascular repair of ruptured abdominal aortic aneurysms  
Christos Karkos, Aristotelis Ifantis, Christina Papadimitriou, Ioannis Pliatsios, Dimitrios Pelekas, Maria-Afroditi Mitka, Konstantinos Papazoglou
- Inflammation as a predictor of abdominal aortic aneurysm growth and rupture: a systematic review of imaging biomarkers  
Hamid Jalalzadeh, Reza Indrakusuma, R.N. Planken, D.A. Legemate, M.J.W. Koelemay, Ron Balm
- The association of mmp9 and mmp13 functional genetic polymorphisms and abdominal aortic aneurysm in a Greek population  
Georgios Makrygiannis, Evanthia Mourmoura, Konstantinos Spanos, Nikolaos Roussas, Aspasia Tsezou, Athanasios Giannoukas
- Can aortic root replacement with a graft affect cardiac function in patients with marfan syndrome?  
Laura Muino Mosquera, Katrien François, Thierry Bové, Daniel De Wolf, Julie De Backer
- Cholesterol precursors in patients with AAA  
Miroslav Prucha, Petr Sedivy, Petr Stadler
- Gene expression signature in patients with abdominal aortic aneurysm  
Miroslav Prucha, Petr Sedivy, Petr Stadler, Pavel Zdrahal
- The natural history of a large aorta is greater cardiovascular risk  
Matthew Bown, David Sidloff, Athanasios Saratzis
- Overview about the value of functional imaging in the management of aortitis  
Bruls Samuel, Courtois Audrey, Nusgens Betty, Defraigne Jean-Olivier, Delvenne Philippe, Hustinx Roland, Moutschen Michel, Sakalihasan Natzi

## Industry sponsored symposium

### Saturday September 17

11.30 - 12.30 | **LivaNova symposium**

Health innovation that matters

#### Perceval Focus Group Belgium

**Prof. M.A. Radermecker, Prof. B. Meuris, Prof. B. Paelinck**

The role of Echo in PRE-Operative, PERI-Operative and POST-Operative setting when using Perceval, **Grégory Hans**

Technical considerations when sizing for a Perceval implantation In-vitro and In-vivo testing, **Parla Astarci**

Treatment indications: recommendations and new options, **Jean-Marc Marnette**


# General information

## Meeting venue

### Crowne Plaza Hotel

9-11, rue du Mont St Martin, Liège, Belgium

[www.crowneplazaliège.be](http://www.crowneplazaliège.be)



## HOTELS

### 1. Crowne Plaza - Congress venue

9-11, rue du Mont St Martin  
[www.crowneplazaliège.be](http://www.crowneplazaliège.be)

### 2. Pentahotel Liège\*\*\*\* (5 min. walk)

100, bd de la Sauvenière  
[www.pentahotels.com](http://www.pentahotels.com)

### 3. Ibis Liège Centre Opéra\*\*\* (5 min. walk)


41, place de la république Française  
[www.ibis.com](http://www.ibis.com)

## REGISTRATION & INFORMATION DESK

Thursday ..... 07.30 - 19.00  
Friday ..... 08.00 - 19.30  
Saturday ..... 08.00 - 17.30

## EXHIBITION HOURS

Thursday ..... 09.30 - 19.00  
Friday ..... 09.00 - 19.30  
Saturday ..... 09.00 - 14.00



Level 1

## EXHIBITORS

BOOTH	INDUSTRIAL
1	MEDTRONIC
2	COOK MEDICAL
3	VITALITEC
4	BARD
5	JOHNSON&JOHNSON MEDICAL
8	EUROSETS
11	ST JUDE MEDICAL
12	HOSPITHERA
13	MAQUET
14	LIVANOVA
16	EDWARDS



# Sponsors 2016

Platinum sponsor

**Medtronic**

Gold sponsor

**LivaNova** **MAQUET**  
Health innovation that matters GETINGE GROUP

Silver sponsors



Edwards



ST. JUDE MEDICAL

Bronze sponsors



PERIPHERAL  
VASCULAR

**EUROSETS**  
MEDICAL DEVICES

**Johnson & Johnson**  
MEDICAL DEVICES COMPANIES



Other sponsor



Mdeon Visa number: 16/V2/4726/005044.

## EVENT COORDINATORS' CONTACTS

**Christine Arzouyan**

General organization

Mobile: +33 613 96 08 70

carzouyan@divine-id.com

**Cyrielle Launoy**

Faculty

claunoy@divine-id.com

**Vérane Bergeron Moreau**

Executive manager

Mobile: +33 621 78 87 16

vbergeron@divine-id.com

## LOCAL CONTACT

**Geneviève Péters**

Scientific program

CHU Liège • Belgium

Tel.: +32 4 366 43 49

genevieve.peters@chu.ulg.ac.be

## ORGANIZATION

divine [id] agency

17, rue Venture • 13001 Marseille • France

Tel.: +33 491 57 19 60

Fax: +33 491 57 19 61

info@divine-id.com

www.divine-id.com

